ESR1 and breast neoplasm: It is now known that PIK3CA is mutationally activated in up to 40% of ER alpha-positive tumors; PTEN levels are decreased in a similar proportion, and AKT2 (up to 5%) and p70S6K (10-20%) may also be overexpressed by amplification in some breast tumors [13].